The candidate is developed as part of a US$6bn collaboration with Japanese giant Daiichi Sankyo.
Analysts believe it will become a blockbuster drug and estimated risk-adjusted peak sales of US$2.6bn.
“This adds to an already strong oncology franchise, and we note accelerating momentum for new launches Enhertu and Calquence,” the broker noted.
“The franchise will underpin double-digit earnings growth as it climbs to 60% of sales by 2030, up from 40% today.”
Shares were trading at 8,279p on Thursday in the late morning.